Morphological examination of surgical material of primary lung cancer after neoadjuvant therapy: recommendations and literature review

Petrova A.D.; Kozlov N.A.; Rogozhin D.V.

doi:https://doi.org/10.17116/patol20258704140

Petrova A.D.

N.N. Blokhin National Medical Research Center of Oncology

ORCID: 0009-0009-8688-1518

Kozlov N.A.

N.N. Blokhin National Medical Research Center of Oncology

ORCID: 0000-0003-3852-3969

Rogozhin D.V.

N.N. Blokhin National Medical Research Center of Oncology

SPIN RSCI: 8742-7598
Scopus AuthorID: 21743507700
ORCID: 0000-0003-0777-9152

Morphological examination of surgical material of primary lung cancer after neoadjuvant therapy: recommendations and literature review

Authors:

Petrova A.D., Kozlov N.A., Rogozhin D.V.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2025;87(4): 40‑46

DOI: 10.17116/patol20258704140

Read: 494 times

Contact the author

Table of contents

To cite this article:

Petrova AD, Kozlov NA, Rogozhin DV. Morphological examination of surgical material of primary lung cancer after neoadjuvant therapy: recommendations and literature review. Russian Journal of Archive of Pathology. 2025;87(4):40‑46. (In Russ.)
https://doi.org/10.17116/patol20258704140

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)

Использование инфографики авторами научных работ

Recommended articles:

Exosomal non-coding rnas as potential biomarkers in the diagnosis and prognosis of lung cancer. Review. Laboratory Service. 2024;(3):42-49

Management before anatomical lung resections: prehabilitation and functional testing. Pirogov Russian Journal of Surgery. 2024;(12):91-98

Prognostic factors and preoperative therapy in resectable intrahepatic cholangiocarcinoma. Pirogov Russian Journal of Surgery. 2025;(1):5-13

Neoadjuvant drug therapy and oncological outcomes in patients with stage I–II breast cancer. P.A. Herzen Journal of Oncology. 2025;(1):5-12

The role of neoadjuvant chemotherapy in the combined treatment of locally advanced non-small cell lung cancer and the prerequisites for a personalized approach to it. P.A. Herzen Journal of Oncology. 2025;(1):19-25

Mediastinal staging in planning the management of patients with non-small cell lung cancer. P.A. Herzen Journal of Oncology. 2025;(2):57-63

The first thousand of VATS anatomical lung resections at the Herzen Moscow Oncology Research Institute. Pirogov Russian Journal of Surgery. 2025;(6):7-18

Prognostic model and calculator for assessing the risk of prolonged pleural effusion after lobectomy. Pirogov Russian Journal of Surgery. 2025;(6):26-34

Fibrosing interstitial lung disease as a risk factor for lung cancer: a review of the literature and clinical case report. Journal of Respiratory Medicine. 2025;(2):51-59

Hemostasis disorders during neoadjuvant therapy in patients with breast cancer. P.A. Herzen Journal of Oncology. 2025;(3):39-44

Abstract:

The degree of pathologic response in non-small cell lung cancer (NSCLC) after neoadjuvant therapy (NAT) has prognostic impact as well as influence on patient’s management. It was shown that the best survival rates were achieved in patients with equals or less than 10% of residual carcinoma (major pathologic response) or with complete absence of invasive carcinoma (complete pathologic response). In 2020 the International Association for the Study of Lung Cancer has published Multidisciplinary Recommendations for pathologic assessment of NSCLC resection specimens after NAT. In this article, we present the main points of the Recommendations taking into account our own experience in evaluating post-therapeutic changes in NSCLC. The article is intended primarily for pathologists practicing in oncological hospitals, but may also be of interest to other practitioners involved in the diagnostics and treatment of lung cancer patients.

Keywords:

gross processing

non-small cell lung cancer

pathological response

neoadjuvant therapy

Authors:

Petrova A.D.

N.N. Blokhin National Medical Research Center of Oncology

ORCID: 0009-0009-8688-1518

Kozlov N.A.

N.N. Blokhin National Medical Research Center of Oncology

ORCID: 0000-0003-3852-3969

Rogozhin D.V.

N.N. Blokhin National Medical Research Center of Oncology

SPIN RSCI: 8742-7598
Scopus AuthorID: 21743507700
ORCID: 0000-0003-0777-9152

Received:

11.06.2025

Accepted:

25.06.2025

Close metadata

References:

Laktionov K.K., Artamonova E.V., Breder V.V., Gorbunova V.A., Demidova I.A., Dengina N.V. Practical recommendations for the drug treatment of nonsmall cell lung cancer. Malignant Tumors. 2022;12(3s2-1):41–59. (In Russ.) https://doi.org/10.18027/2224-5057-2022-12-3s2-41-59
Houda I, Dickhoff C, Uyl-de Groot CA, Damhuis RAM, Reguart N, Provencio M, Levy A, Dziadziuszko R, Pompili C, Di Maio M, Thomas M, Brunelli A, Popat S, Senan S, Bahce I. Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective. Lancet Reg Health Eur. 2024;38:100841. https://doi.org/10.1016/j.lanepe.2024.100841
Saqi A, Leslie KO, Moreira AL, Lantuejoul S, Shu CA, Rizvi NA, Sonett JR, Tajima K, Sun SW, Gitlitz BJ, Colby TV. Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice. JTO Clin Res Rep. 2022;3(5):100310. https://doi.org/10.1016/j.jtocrr.2022.100310
Gavioli M, Luppi G, Losi L, Bertolini F, Santantonio M, Falchi AM, D’Amico R, Conte PF, Natalini G. Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer. Dis Colon Rectum. 2005;48(10):1851-7. https://doi.org/10.1007/s10350-005-0133-6
Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol. 2015;28(9):1185-201. https://doi.org/10.1038/modpathol.2015.74
Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Müller KM. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol. 1997;123(9):469-77. https://doi.org/10.1007/BF01192200
Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba II, Swisher SG; University of Texas M. D. Anderson Lung Cancer Collaborative Research Group. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012;7(5):825-32. https://doi.org/10.1097/JTO.0b013e318247504a
Hellmann MD, Chaft JE, William WN Jr, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG; University of Texas MD Anderson Lung Cancer Collaborative Group. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15(1):e42-50. https://doi.org/10.1016/S1470-2045(13)70334-6.
Nicholson AG, Kerr K, Gosney (J. Standards and datasets for reporting cancers Dataset for histopathological reporting of lung cancer September 2018. Royal College of Pathologists. https://www.rcpath.org/static/265cdf74-3376-40b0-b7d0e3ed8a588398/G048-Dataset-for-histopathological-reporting-of-lung-cancer.pdf
Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. J Thorac Oncol. 2020 ;15(5):709-740. https://doi.org/10.1016/j.jtho.2020.01.005
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8(7):823-59. https://doi.org/10.1097/JTO.0b013e318290868f
Weissferdt A, Leung CH, Lin H, Sepesi B, William WN, Swisher SG, Cascone T, Lee JJ, Pataer A. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Mod Pathol. 2024;37(1):100353. https://doi.org/10.1016/j.modpat.2023.100353
Dacic S, Travis W, Redman M, Saqi A, Cooper WA, Borczuk A, Chung JH, Glass C, Lopez JM, Roden AC, Sholl L, Weissferdt A, et al.. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. J Thorac Oncol. 2023;18(10):1290-1302. https://doi.org/10.1016/j.jtho.2023.07.017
Qu Y, Emoto K, Eguchi T, Aly RG, Zheng H, Chaft JE, Tan KS, Jones DR, Kris MG, Adusumilli PS, Travis WD. Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. J Thorac Oncol. 2019;14(3):482-493. https://doi.org/10.1016/j.jtho.2018.11.017
Liu, X., Sun, W., Wu, J. et al. Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer. Mod Pathol. 2021; 34: 1990–1998. https://doi.org/10.1038/s41379-021-00871-1
Pataer A, Weissferdt A, Correa AM, Vaporciyan AA, Sepesi B, Heymach JV, Berezowska S, Cascone T, Swisher SG. Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. JTO Clin Res Rep. 2022;3(11):100420. https://doi.org/10.1016/j.jtocrr.2022.100420
Pataer A, Weissferdt A, Vaporciyan AA, Correa AM, Sepesi B, Wistuba II, Heymach JV, Cascone T, Swisher SG. Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. J Thorac Oncol. 2021;16(8):1289-1297. https://doi.org/10.1016/j.jtho.2021.03.029
Weissferdt A, Pataer A, Swisher SG, Heymach JV, Gibbons DL, Cascone T, Sepesi B. Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. Lung Cancer. 2021;154:76-83. https://doi.org/10.1016/j.lungcan.2021.02.014